Passing of Genmab A/S' Annual General Meeting
Genmab A/S
25.04.2012 15:57
---------------------------------------------------------------------------
- At Genmab A/S' Annual General Meeting held today on April 25, 2012 the Annual
Report for 2011 was approved
- Discharge was given to the Board of Directors and the Executive Management
and the year's loss was carried forward
- A member of the Board of Directors was re-elected
- PricewaterhouseCoopers was re-elected as auditor of the Company
- The proposal from the Board of Directors on general guidelines for
incentive-based remuneration, the proposal on the Board of Directors'
remuneration for 2012 and the proposals to amend Article 5 were adopted
Copenhagen, Denmark; April 25, 2012 - Genmab A/S (OMX: GEN) held its Annual
General Meeting, today April 25, 2012 at 2:00 PM at Tivoli Hotel & Congress
Center, Arni Magnussons Gade 2, DK-1577 Copenhagen V, Denmark.
At the meeting Chairman of the Board of Directors Dr. Michael B. Widmer gave -
on behalf of the Board of Directors - a report on the Company's activities
during the past year. Chief Executive Officer Jan van de Winkel presented plans
for the year ahead, and Chief Financial Officer David Eatwell presented the
Annual Report for 2011 endorsed by the auditors. The report was approved and
discharge was given to the Board of Directors and the Executive Management.
It was decided that the year's loss of DKK 611 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.
Hans Henrik Munch-Jensen was re-elected to the Board of Directors for a two
year period.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected
as the Company's auditor.
The General Meeting adopted the proposals from the Board of Directors, as
follows:
- The proposal to adopt revised general guidelines for incentive-based
remuneration for the Board of Directors and the Executive Management.
- The proposal to adopt the Board of Directors' remuneration for 2012.
- The proposal to amend Article 5 to authorize the Board of Directors to issue
additional warrants - without pre-emption rights for the existing shareholders
- that give the right to subscribe up to nominally DKK 250,000 shares in the
Company to members of the Company's Board of Directors, the Company's employees
and consultants as well as employees and consultants of the Company's
subsidiaries and to implement the corresponding capital increases. According to
the amended Article 5, the Board of Directors will be allowed to reuse or
reissue lapsed non-exercised warrants, if any, issued under this new
authorization as well as under the remainder of the existing authorization.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 10
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=389271
News Source: NASDAQ OMX
25.04.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Genmab A/S
25.04.2012 15:57
---------------------------------------------------------------------------
- At Genmab A/S' Annual General Meeting held today on April 25, 2012 the Annual
Report for 2011 was approved
- Discharge was given to the Board of Directors and the Executive Management
and the year's loss was carried forward
- A member of the Board of Directors was re-elected
- PricewaterhouseCoopers was re-elected as auditor of the Company
- The proposal from the Board of Directors on general guidelines for
incentive-based remuneration, the proposal on the Board of Directors'
remuneration for 2012 and the proposals to amend Article 5 were adopted
Copenhagen, Denmark; April 25, 2012 - Genmab A/S (OMX: GEN) held its Annual
General Meeting, today April 25, 2012 at 2:00 PM at Tivoli Hotel & Congress
Center, Arni Magnussons Gade 2, DK-1577 Copenhagen V, Denmark.
At the meeting Chairman of the Board of Directors Dr. Michael B. Widmer gave -
on behalf of the Board of Directors - a report on the Company's activities
during the past year. Chief Executive Officer Jan van de Winkel presented plans
for the year ahead, and Chief Financial Officer David Eatwell presented the
Annual Report for 2011 endorsed by the auditors. The report was approved and
discharge was given to the Board of Directors and the Executive Management.
It was decided that the year's loss of DKK 611 million be carried forward by
transfer to accumulated deficit, as stated in the Annual Report.
Hans Henrik Munch-Jensen was re-elected to the Board of Directors for a two
year period.
PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected
as the Company's auditor.
The General Meeting adopted the proposals from the Board of Directors, as
follows:
- The proposal to adopt revised general guidelines for incentive-based
remuneration for the Board of Directors and the Executive Management.
- The proposal to adopt the Board of Directors' remuneration for 2012.
- The proposal to amend Article 5 to authorize the Board of Directors to issue
additional warrants - without pre-emption rights for the existing shareholders
- that give the right to subscribe up to nominally DKK 250,000 shares in the
Company to members of the Company's Board of Directors, the Company's employees
and consultants as well as employees and consultants of the Company's
subsidiaries and to implement the corresponding capital increases. According to
the amended Article 5, the Board of Directors will be allowed to reuse or
reissue lapsed non-exercised warrants, if any, issued under this new
authorization as well as under the remainder of the existing authorization.
About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company's first marketed
antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic
leukemia in patients who are refractory to fludarabine and alemtuzumab after
less than eight years in development. Genmab's validated and next generation
antibody technologies are expected to provide a steady stream of future product
candidates. Partnering of innovative product candidates and technologies is a
key focus of Genmab's strategy and the company has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.
Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com
This Company Announcement contains forward looking statements. The words
'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab's most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.
Genmab(r); the Y-shaped Genmab logo(r); HuMax(r); HuMax-CD20(r); HuMax(r)-EGFr;
HuMax(r)-IL8; HuMax(r)-TAC; HuMax(r)-CD38; HuMax(r)-TF; HuMax(r)-Her2; HuMax(r)-cMet,
HuMax(r)-CD74, DuoBody(tm) and UniBody(r) are all trademarks of Genmab A/S. Arzerra(r)
is a trademark of GlaxoSmithKline.
Company Announcement no. 10
CVR no. 2102 3884
Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark
Click on, or paste the following link into your web browser, to view the associated documents
https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=389271
News Source: NASDAQ OMX
25.04.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Genmab A/S
Denmark
Phone:
Fax:
E-mail:
Internet:
ISIN: DK0010272202
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------